NCT05747677

A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19

A Single-Arm Clinical Study Evaluating the Efficacy of Post-Exposure Prophylaxis , Safety, and Tolerability of HH-120 Nasal Spray in Close Contacts of SARS-CoV-2

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Beijing Ditan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy of post-exposure prevention and safety of HH-120 nasal spray in participants who are caregivers of hospitalized patients infected with SARS-CoV-2. HH-120 nasal spray are administrated 8-10 times to the participants per day until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.

Conditions

• COVID-19
• SARS-CoV-2 Infection

Interventions

Type	Name	Description
DRUG	HH-120 Nasal Spray	HH-120 nasal spray, 1 spray to each nostril of the participant each time,8-10 times per day, until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.

Timeline

• Start date: 2022-06-14
• Primary completion: 2023-02-06
• Completion: 2023-02-06
• First posted: 2023-02-28
• Last updated: 2023-02-28

Locations

1 site across 1 country: China